Brenda Stanton

Brenda Stanton is an experienced professional in ocular disease evaluation and quality assurance, currently serving as Ocular Disease Evaluator II at Doheny Eye Institute since December 2020. Responsibilities include training new staff, performing document reviews, making final assessment calls, and assisting in the development of grading protocols. Previous roles at Doheny Eye Institute include Ocular Disease Evaluator I and QA/QC Coordinator. Prior experience includes working as a Cell Therapy Specialist at Kite Pharma, and various positions in quality assurance and control at Astellas Pharma and Helica Biosystems, Inc. Brenda Stanton holds a Bachelor of Science in Cell and Developmental Biology from California State University, Fullerton.